Beam Therapeutics BEAM Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $31.74M+325% | $114.11M+280% | $9.7M-32.0% | $8.47M-28.1% | $7.47M+0.8% | ||
| $104.52M+5.8% | $99.28M-2.1% | $109.77M+16.5% | $101.76M+16.9% | $98.82M+16.5% | ||
| $34.43M+23.2% | $32.28M+12.6% | $26.74M+0.8% | $26.86M-9.3% | $27.94M+4.6% | ||
| $138.95M+9.6% | $131.55M+1.1% | $136.51M+13.0% | $128.62M+10.2% | $126.76M+13.6% | ||
| -$107.22M+10.1% | -$17.45M+82.6% | -$126.81M-19.1% | -$120.15M-14.5% | -$119.29M-14.6% | ||
| -337.8%+1,259pp | -15.3%+317pp | -1,307.6%-561pp | -1,419.2%-528pp | -1,596.9%-192pp | ||
| $12.9M+17.7% | $261.74M+2,603% | $14.08M+43.2% | $17.86M+28.6% | $10.96M+101% | ||
| -$94.32M+12.9% | —— | -$112.73M-16.6% | -$102.29M-12.3% | -$108.33M-9.8% | ||
| -297.2%+1,153pp | —— | -1,162.4%-485pp | -1,208.3%-435pp | -1,450.2%-119pp | ||
| -$0.91+26.0% | —— | -$1.10+6.0% | -$1.00+9.9% | -$1.23-1.7% | ||
| -$101.61M+10.7% | -$11.78M+87.5% | -$121.25M-20.0% | -$114.61M-15.4% | -$113.76M-15.3% | ||
| -320.2%+1,203pp | -10.3%+304pp | -1,250.3%-542pp | -1,353.8%-510pp | -1,522.9%-191pp | ||
| -$107.22M+10.1% | -$17.45M+82.6% | -$126.81M-19.1% | -$120.15M-14.5% | -$119.29M-14.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Beam Therapeutics's revenue?
- Beam Therapeutics (BEAM) generated $164.0M in revenue over the trailing twelve months, up 158.0% year over year.
- Is Beam Therapeutics profitable?
- Beam Therapeutics is not currently profitable: it reported a net loss of $417.7M over the trailing twelve months, a -742.7% net margin.
- What is Beam Therapeutics's earnings per share?
- Beam Therapeutics's diluted EPS over the trailing twelve months is $-4.24.
- Where does Beam Therapeutics's income statement data come from?
- Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
